Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIST: Tenofovir-Lamivudine-Dolutegravir in Second-line HIV Treatment
NCT03991013Phase 2Completed
- Sponsor
- University of Cape Town
- Start
- Aug 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by University of Cape Town. Started Aug 2019; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03991013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991013.